Literature DB >> 12578434

Family study of affective spectrum disorder.

James I Hudson1, Barbara Mangweth, Harrison G Pope, Christine De Col, Armand Hausmann, Sarah Gutweniger, Nan M Laird, Wilfried Biebl, Ming T Tsuang.   

Abstract

BACKGROUND: Affective spectrum disorder (ASD) represents a group of psychiatric and medical conditions, each known to respond to several chemical families of antidepressant medications and hence possibly linked by common heritable abnormalities. Forms of ASD include major depressive disorder (MDD), attention-deficit/hyperactivity disorder, bulimia nervosa, cataplexy, dysthymic disorder, fibromyalgia, generalized anxiety disorder, irritable bowel syndrome, migraine, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder, and social phobia. Two predictions of the ASD hypothesis were tested: that ASD, taken as a single entity, would aggregate in families and that MDD would coaggregate with other forms of ASD in families.
METHODS: Probands with and without MDD, together with their first-degree relatives, were interviewed using the Structured Clinical Interview for DSM-IV and a supplemental interview for other forms of ASD. The familial aggregation and coaggregation of disorders were analyzed using proband predictive logistic regression models, including a novel bivariate model for the presence or absence of each of 2 disorders in a relative as predicted by the presence or absence of each of 2 disorders in the associated proband.
RESULTS: In the 178 interviewed relatives of 64 probands with MDD and 152 relatives of 58 probands without MDD, the estimated odds ratio (95% confidence interval) for the familial aggregation of ASD as a whole was 2.5 (1.4-4.3; P =.001) and for the familial coaggregation of MDD with at least one other form of ASD was 1.9 (1.1-3.2; P =.02).
CONCLUSIONS: Affective spectrum disorder aggregates strongly in families, and MDD displays a significant familial coaggregation with other forms of ASD, taken collectively. These results suggest that forms of ASD may share heritable pathophysiologic features.

Entities:  

Mesh:

Year:  2003        PMID: 12578434     DOI: 10.1001/archpsyc.60.2.170

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  34 in total

Review 1.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 2.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

3.  The contribution of familial internalizing and externalizing liability factors to borderline personality disorder.

Authors:  J I Hudson; M C Zanarini; K S Mitchell; L W Choi-Kain; J G Gunderson
Journal:  Psychol Med       Date:  2014-01-09       Impact factor: 7.723

4.  Family history of mental illness or alcohol abuse and the irritable bowel syndrome.

Authors:  James R Knight; G Richard Locke; Alan R Zinsmeister; Cathy D Schleck; Nicholas J Talley
Journal:  J Psychosom Res       Date:  2014-12-03       Impact factor: 3.006

5.  Controlled follow-up study of physical and psychosocial functioning of adolescents with juvenile primary fibromyalgia syndrome.

Authors:  Susmita Kashikar-Zuck; Irina S Parkins; Tracy V Ting; Emily Verkamp; Anne Lynch-Jordan; Murray Passo; Thomas Brent Graham
Journal:  Rheumatology (Oxford)       Date:  2010-08-05       Impact factor: 7.580

6.  Depression: relationships to sleep paralysis and other sleep disturbances in a community sample.

Authors:  Mariana Szklo-Coxe; Terry Young; Laurel Finn; Emmanuel Mignot
Journal:  J Sleep Res       Date:  2007-09       Impact factor: 3.981

Review 7.  Pharmaceutical treatment options for fibromyalgia.

Authors:  Leslie J Crofford
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

Review 8.  Pathophysiology of fibromyalgia.

Authors:  Laurence A Bradley
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

9.  Estimating disease prevalence using relatives of case and control probands.

Authors:  Kristin N Javaras; Nan M Laird; James I Hudson; Brian D Ripley
Journal:  Biometrics       Date:  2009-05-18       Impact factor: 2.571

10.  Treatment of chronic fatigue syndrome: findings, principles and strategies.

Authors:  Patrick Luyten; Boudewijn Van Houdenhove; Chi-Un Pae; Stefan Kempke; Peter Van Wambeke
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.